1988
On the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies
1983
Advances in cancer therapeutics: chemotherapy.
DeVita V. Advances in cancer therapeutics: chemotherapy. Progress In Clinical And Biological Research 1983, 132A: 47-69. PMID: 6634746.Peer-Reviewed Original ResearchConceptsTumor massEffectiveness of combination chemotherapyResistance to anti-cancer drugsCancer chemotherapyInvariable inverse relationshipPathways of drug resistanceOutcome of cancer chemotherapyOutcome of surgeryResistance to chemotherapyCell numberHistory of cancerNatural history of cancerOrigin of human cancerCombination chemotherapyAnti-cancer drugsLocal treatmentChemotherapyDrug resistanceHuman malignanciesRadiotherapyCancer therapeuticsNatural historyHuman cancersSurgeryCancer
1977
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original Research
1975
American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival
Arseneau J, Canellos G, Banks P, Berard C, Gralnick H, DeVita V. American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival. The American Journal Of Medicine 1975, 58: 314-321. PMID: 1115074, DOI: 10.1016/0002-9343(75)90597-5.Peer-Reviewed Original ResearchConceptsLDH levelsTumor massComplete remissionIU/Central nervous system involvementSerum lactic dehydrogenase levelsMonths of treatmentNervous system involvementSerum LDH levelsAmerican Burkitt's lymphomaResults of therapyLactic dehydrogenase levelsLarge tumor massParenteral cyclophosphamideClinical characteristicsClinicopathologic studyLocalized diseaseClinical factorsComplete responseFrequent siteSystem involvementTumor regressionDehydrogenase levelsSudden deathBurkitt's lymphoma
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activity